Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$17.04
neg -0.26
-1.50%
Today's Range: 16.89 - 17.31 | TEVA Avg Daily Volume: 15,081,600
Last Update: 08/21/17 - 4:01 PM EDT
Volume: 11,703,202
YTD Performance: -52.28%
Open: $17.28
Previous Close: $17.30
52 Week Range: $16.81 - $53.96
Oustanding Shares: 1,016,000,000
Market Cap: 17,373,600,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 4 4 4
Moderate Buy 0 1 1 1
Hold 14 10 10 8
Moderate Sell 0 0 0 0
Strong Sell 2 0 0 1
Mean Rec. 2.96 2.40 2.40 2.50
Latest Dividend: 0.07
Latest Dividend Yield: 5.49%
Dividend Ex-Date: 08/25/17
Price Earnings Ratio: 3.33
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
3.33 0.00 35.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-41.69% -67.39% -66.98%
GROWTH 12 Mo 3 Yr CAGR
Revenue 11.50 0.10 0.03
Net Income -80.50 -0.80 -0.37
EPS -96.20 -0.90 -0.64
Earnings for TEVA:
EBITDA 6.18B
Revenue 21.90B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $1.05 $1.12 $4.19 $3.92
Number of Analysts 5 5 7 7
High Estimate $1.06 $1.24 $4.32 $4.63
Low Estimate $1.03 $1.00 $4.06 $3.50
Prior Year $1.28 $1.36 $5.06 $4.19
Growth Rate (Year over Year) -18.28% -17.79% -17.11% -6.61%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Aug 18, 2017 | 11:30 AM EDT
I am working incrementally into some small stocks with great long-term value.
RMPIA
By

Paul Price

 | Aug 16, 2017 | 7:00 AM EDT
The drug stock deserved to go down, but the resulting selloff is an overreaction.
By

Paul Price

 | Aug 9, 2017 | 7:00 AM EDT
If you want to reap big gains, read, understand and buy when the numbers make sense.
By

Paul Price

 | Aug 8, 2017 | 8:30 AM EDT
A couple of new prospects emerge.
RMPIA
By

Doug Kass

 | Aug 7, 2017 | 5:01 PM EDT
The market stood its ground and then some today:   * A buy program was the last program standing. * The Nasdaq regained streng …

bearishMorgan Stanley Cuts Teva to Underweight

Aug 7, 2017 | 9:08 AM EDT
Teva Pharmaceuticals was downgraded at Morgan Stanley to "Underweight" from "Overweight" with a $16 price target.
RMPIA
By

Paul Price

 | Aug 7, 2017 | 7:00 AM EDT
'Buy low and sell high' is easier said than done, but you can fight your fear with TEVA.
RMPIA
By

Jim Cramer and the AAP Team

 | Aug 6, 2017 | 10:00 AM EDT
Callout: Results and guidance lift markets, dodging D.C. drama.
RMPIA
By

Doug Kass

 | Aug 4, 2017 | 1:24 PM EDT
Further Teva (TEVA) losses are plaguing Allergan (AGN) today.

bearishTeva Cut to Market Perform at Bernstein

Aug 4, 2017 | 8:56 AM EDT
Teva Pharmaceuticals was downgraded at Bernstein to "Market Perform" from "Outperform" with a $28 price target.
we will add this here to cheaply protect our downside a bit BOUGHT SPY SEP...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.